PMID- 27931844
OWN - NLM
STAT- MEDLINE
DCOM- 20170119
LR  - 20220419
IS  - 1879-0461 (Electronic)
IS  - 1040-8428 (Linking)
VI  - 108
DP  - 2016 Dec
TI  - Dendritic cells in hematological malignancies.
PG  - 86-96
LID - S1040-8428(16)30258-X [pii]
LID - 10.1016/j.critrevonc.2016.10.006 [doi]
AB  - Dendritic cells (DCs) are bone-marrow-derived immune cells accounted for a 
      crucial role in initiating and modulating the adaptive immune response and 
      supporting the innate immune response independently from T cells. While 
      functioning as the most effective antigen-presenting cells within the immune 
      system, DCs can otherwise induce tolerance in central and peripheral lymphoid 
      organs acting therefore as suppressors rather than stimulators of the immune 
      response. Within mechanisms regulating antitumor immunity, DCs can capture 
      antigens from viable or damaged tumor cells and present the processed peptides to 
      T-cells to prompt the generation and maintenance of an effective tumor-specific 
      T-cell response. Upon a complex cross-talk with other cellular components of the 
      tumor microenvironment, DCs can, on the other hand, exert a potent 
      antigen-dependent and -independent tolerogenic function by favoring the process 
      of tumor immune evasion. Due to this dual-role in balancing antitumor immunity 
      and tolerance, possibly linked to distinct developmental stages and functional 
      subsets, several studies have addressed the regulatory significance of DCs in 
      different types of malignancies. This review summarizes the most significant 
      pieces of evidence highlighting the critical relevance of bone marrow-derived DCs 
      within the immune pathways regulating pathogenesis and progression of hemopoietic 
      tumors.
CI  - Copyright A(c) 2016 Elsevier Ireland Ltd. All rights reserved.
FAU - Galati, Domenico
AU  - Galati D
AD  - Hematology-Oncology and Stem-Cell Transplantation Unit, Department of Hematology, 
      National Cancer Institute, Fondazione 'G. Pascale', IRCCS, Via Mariano Semmola 
      49, 80131 Naples, Italy. Electronic address: d.galati@istitutotumori.na.it.
FAU - Corazzelli, Gaetano
AU  - Corazzelli G
AD  - Hematology-Oncology and Stem-Cell Transplantation Unit, Department of Hematology, 
      National Cancer Institute, Fondazione 'G. Pascale', IRCCS, Via Mariano Semmola 
      49, 80131 Naples, Italy.
FAU - De Filippi, Rosaria
AU  - De Filippi R
AD  - Department of Clinical Medicine and Surgery, Federico II University, Via Sergio 
      Pansini 5, 80131 Naples, Italy.
FAU - Pinto, Antonio
AU  - Pinto A
AD  - Hematology-Oncology and Stem-Cell Transplantation Unit, Department of Hematology, 
      National Cancer Institute, Fondazione 'G. Pascale', IRCCS, Via Mariano Semmola 
      49, 80131 Naples, Italy.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20161022
PL  - Netherlands
TA  - Crit Rev Oncol Hematol
JT  - Critical reviews in oncology/hematology
JID - 8916049
SB  - IM
MH  - Animals
MH  - B-Lymphocytes/immunology
MH  - Cell Differentiation
MH  - Dendritic Cells/cytology/*immunology
MH  - Hematologic Neoplasms/*immunology
MH  - Humans
MH  - T-Lymphocytes/immunology
OTO - NOTNLM
OT  - Dendritic cells
OT  - Hematological malignancies
OT  - Leukemia
OT  - Lymphomas
OT  - Myeloid neoplasms
OT  - Plasma cell neoplasms
EDAT- 2016/12/10 06:00
MHDA- 2017/01/20 06:00
CRDT- 2016/12/10 06:00
PHST- 2016/04/28 00:00 [received]
PHST- 2016/09/05 00:00 [revised]
PHST- 2016/10/18 00:00 [accepted]
PHST- 2016/12/10 06:00 [entrez]
PHST- 2016/12/10 06:00 [pubmed]
PHST- 2017/01/20 06:00 [medline]
AID - S1040-8428(16)30258-X [pii]
AID - 10.1016/j.critrevonc.2016.10.006 [doi]
PST - ppublish
SO  - Crit Rev Oncol Hematol. 2016 Dec;108:86-96. doi: 
      10.1016/j.critrevonc.2016.10.006. Epub 2016 Oct 22.